Responsum Health Facilitates Patient Participation in Clinical Trials
Initiative to increase awareness and facilitate patient participation in the new Renovel Study
[WASHINGTON, D.C., February 21, 2023] —Today, Responsum Health (Responsum), a leading developer of innovative patient engagement platforms, announced another collaboration with Aldeyra Therapeutics, this time to support the Renovel Study.
The joint effort aims to increase awareness and provide a simple way for patients to find and participate in clinical trials. Patient participation in clinical trials plays a critical role in our understanding of diseases and the development of new treatments. Patients with nephrotic syndrome will have the opportunity to contribute to the research and development of new therapies and be part of a community working toward this common goal.
Responsum will inform and pre-screen potential participants, then connect them with trial doctors for the Renovel Study. The Renovel Study is a Phase 2 clinical trial investigating experimental drug ADX-629 in people with nephrotic syndrome (NS), including minimal change disease and focal segmental glomerulosclerosis. Despite recent advancements in healthcare, the underlying cause of nephrotic syndrome remains unknown, and many patients still experience frequent relapses and depend on prednisone to maintain remission.
Nephrotic syndrome describes a group of rare kidney diseases characterized by swelling, low appetite, fatigue, proteinuria, and foam in the urine. Kidneys have tiny filters, called glomeruli, that filter toxins out of the blood and keep nutrients (like protein) inside the body. In people with NS, these filters become damaged and the body then loses nutrients, specifically protein, through the urine. The Renovel Study may offer new hope for some patients living with nephrotic syndrome.
As part of the campaign, Responsum will educate patients about the Renovel Study, incluing the benefits and risks of participating in clinical trials. It will also connect pre-qualified patients with trial doctors at leading research hospitals and clinics in the United States. All trial-related services are provided at no cost to patients, and participants may be eligible for reimbursement for their time and travel.
“Our mission is to empower patients and provide them easy access to new clinical trials. By connecting patients with trial doctors and providing education and support, we hope to make a real difference in the lives of those affected by nephrotic syndrome,” said Responsum Health Founder and CEO Andrew Rosenberg. “Trial recruitment is an area of growing expertise and accomplishment for Responsum, and it represents an exciting new avenue of growth for our company.”
About Responsum Health
Responsum (Latin for “the answer”) is a disruptive and innovative healthcare startup company whose mission is to build and support online knowledge communities of and for people living with chronic conditions who seek ways to live their best lives.
Responsum Health provides free, condition-specific patient engagement platforms and apps that monitor, search, and curate news articles, blog posts, and scientific papers from the Internet, then generate personalized Newsfeeds of article summaries vetted by partner patient groups and subject matter experts.
Responsum platforms also enable patients to organize their personal health data, find local patient support groups and services, participate in clinical trials, and share their experiences with each other through a moderated community chat.
Today, thousands of patients and caregivers rely on Responsum Health for their daily dose of news and education in areas as diverse as Long COVID, pulmonary fibrosis, chronic kidney disease, uterine fibroids, glaucoma, and menopause.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company devoted to developing innovative medicines to improve the lives of patients with immune-mediated diseases. Their approach is to create therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity.
Aldeyra is the leader in the discovery and development of novel reactive aldehydes species (RASP) modulators as well as other candidates for retinal diseases.
For more information, please contact Bridget Pfeuffer at email@example.com or (202) 480-9607. You can also visit our website at https://responsumhealth.com